Search - tctmd.com

Displaying 601 - 620 of 631

Sort: Relevancy | Date

News Daily News

USPSTF: Not Enough Evidence to Recommend Routine Lipid Screening in Children and Adolescents

Michael O'Riordan

August 09, 2016

News Daily News

Prevention Efforts Seem to Be Paying Off as Acute MIs Continue Slide

Todd Neale

August 08, 2016

News Daily News

阿波罗月球宇航员死于心脏病导致专家探讨深空心血管安全问题

Michael O'Riordan

August 01, 2016

News Daily News

Las Muertes por Causas Cardiovasculares de los Astronautas del Proyecto Apolo Plantean Cuestiones de Seguridad CV en el Espacio Profundo

Michael O'Riordan

August 01, 2016

News Daily News

Apollo Lunar Astronauts Dying of Heart Disease Pose CV Safety Questions for Deep Space

Michael O'Riordan

August 01, 2016

News Daily News

药物治疗的使用不足与高龄患者不良事件增多相关

Michael O'Riordan

July 21, 2016

News Daily News

Underuse of Medical Therapy Linked With Increased Adverse Events in Very Elderly

Michael O'Riordan

July 21, 2016

News Daily News

La Infrautilización del Tratamiento Médico se asocia a Más Episodios Adversos en Pacientes Muy Ancianos

Michael O'Riordan

July 21, 2016

News Daily News

Sitting Pretty: Only Prolonged Sedentary Time Linked With Incident CVD Risk

Michael O'Riordan

July 15, 2016

News Daily News

AstraZeneca Strives to Block Generic Crestor as Observers Call Foul

Michael O'Riordan

July 13, 2016

News Daily News

Time for Niacin to Be ‘Relegated to Medical History’ as HPS2-THRIVE Analysis Confirms Drug’s Failings

Michael O'Riordan

July 12, 2016

News Daily News

Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina

Michael O'Riordan

June 30, 2016

News Daily News

FDA 顾问小组小范围建议使用糖尿病药物 empagliflozin 来改善 CVD 死亡率

Michael O'Riordan

June 30, 2016

News Daily News

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Michael O'Riordan

June 30, 2016

News Daily News

Media Scrutiny Over Risks and Benefits of Statins Impacts Patient Use

Michael O'Riordan

June 28, 2016

News Daily News

利拉鲁肽超越 FDA 安全预期，可降低心血管疾病的死亡率：LEADER

Michael O'Riordan

June 14, 2016

News Daily News

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Michael O'Riordan

June 14, 2016

News Daily News

Estudio LEADER: Liraglutide se Salta la Valla de Seguridad de la FDA al Confirmarse un Descenso de la Mortalidad Cardiovascular

Michael O'Riordan

June 14, 2016

News Daily News

胆固醇治疗试验协作再次审视他汀类药物与不良事件之间的关系

Michael O'Riordan

June 13, 2016

News Daily News

La Colaboración de Ensayistas para el Tratamiento del Colesterol Vuelve a Analizar los Episodios Adversos secundarios a las Estatinas

Michael O'Riordan

June 13, 2016

Advertisement

USPSTF: Not Enough Evidence to Recommend Routine Lipid Screening in Children and Adolescents

Prevention Efforts Seem to Be Paying Off as Acute MIs Continue Slide

阿波罗月球宇航员死于心脏病导致专家探讨深空心血管安全问题

Las Muertes por Causas Cardiovasculares de los Astronautas del Proyecto Apolo Plantean Cuestiones de Seguridad CV en el Espacio Profundo

Apollo Lunar Astronauts Dying of Heart Disease Pose CV Safety Questions for Deep Space

药物治疗的使用不足与高龄患者不良事件增多相关

Underuse of Medical Therapy Linked With Increased Adverse Events in Very Elderly

La Infrautilización del Tratamiento Médico se asocia a Más Episodios Adversos en Pacientes Muy Ancianos

Sitting Pretty: Only Prolonged Sedentary Time Linked With Incident CVD Risk

AstraZeneca Strives to Block Generic Crestor as Observers Call Foul

Time for Niacin to Be ‘Relegated to Medical History’ as HPS2-THRIVE Analysis Confirms Drug’s Failings

Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina

FDA 顾问小组小范围建议使用糖尿病药物 empagliflozin 来改善 CVD 死亡率

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Media Scrutiny Over Risks and Benefits of Statins Impacts Patient Use

利拉鲁肽超越 FDA 安全预期，可降低心血管疾病的死亡率：LEADER

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Estudio LEADER: Liraglutide se Salta la Valla de Seguridad de la FDA al Confirmarse un Descenso de la Mortalidad Cardiovascular

胆固醇治疗试验协作再次审视他汀类药物与不良事件之间的关系

La Colaboración de Ensayistas para el Tratamiento del Colesterol Vuelve a Analizar los Episodios Adversos secundarios a las Estatinas

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content